| 1 |
Lipid nanoparticles for mRNA delivery
Xucheng Hou, Tal Z. Zaks, Róbert Langer et al. · Nature Reviews Materials
ReviewOpen access |
10 Aug 2021 |
3,994 |
| 2 |
SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness
Kizzmekia S. Corbett et al. · Nature
Open access |
5 Aug 2020 |
1,695 |
| 3 |
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Evan J. Anderson et al. · New England Journal of Medicine
Open access |
29 Sep 2020 |
1,641 |
| 4 |
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
Peter B. Gilbert et al. · Science
Open access |
6 Jan 2022 |
1,218 |
| 5 |
Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines
Kimberly J. Hassett, Kerry E. Benenato, Eric Jacquinet et al. · Molecular Therapy — Nucleic Acids
Open access |
10 Feb 2019 |
937 |
| 6 |
Pharmaceutical cocrystals: along the path to improved medicines
Naga Kiran Duggirala, Miranda L. Perry, Örn Almarsson et al. · Chemical Communications
|
3 Nov 2015 |
935 |
| 7 |
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
Jeffrey S. Weber et al. · The Lancet
|
21 Jan 2024 |
871 |
| 8 |
Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination
Alicia T. Widge et al. · New England Journal of Medicine
Open access |
3 Dec 2020 |
831 |
| 9 |
A Novel Amino Lipid Series for mRNA Delivery: Improved Endosomal Escape and Sustained Pharmacology and Safety in Non-human Primates
Staci Sabnis, E. Sathyajith Kumarasinghe, Timothy Salerno et al. · Molecular Therapy
Open access |
18 Mar 2018 |
828 |
| 10 |
Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
Nicole A. Doria‐Rose et al. · New England Journal of Medicine
Open access |
6 Apr 2021 |
758 |
| 11 |
Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses
Kapil Bahl, Joe J. Senn, Olga Yuzhakov et al. · Molecular Therapy
Open access |
27 Apr 2017 |
664 |
| 12 |
A Bivalent Omicron-Containing Booster Vaccine against Covid-19
Spyros Chalkias, Charles Harper, Keith W. Vrbicky et al. · New England Journal of Medicine
Open access |
16 Sep 2022 |
659 |
| 13 |
Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants
Amarendra Pegu et al. · Science
Open access158 authors |
12 Aug 2021 |
605 |
| 14 |
Naturally-occurring cholesterol analogues in lipid nanoparticles induce polymorphic shape and enhance intracellular delivery of mRNA
Siddharth Patel, N. Ashwanikumar, Ema Robinson et al. · Nature Communications
Open access |
20 Feb 2020 |
591 |
| 15 |
mRNA structure regulates protein expression through changes in functional half-life
David Mauger, B. Joseph Cabral, Vladimir Presnyak et al. · Proceedings of the National Academy of Sciences
Open access |
11 Nov 2019 |
588 |
| 16 |
Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants
Hung Fu Tseng, Bradley K. Ackerson, Yi Luo et al. · Nature Medicine
Open access |
21 Feb 2022 |
561 |
| 17 |
Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults
Eleanor M. P. Wilson et al. · New England Journal of Medicine
Open access |
13 Dec 2023 |
499 |
| 18 |
Human 5′ UTR design and variant effect prediction from a massively parallel translation assay
Paul J. Sample, Ban Wang, David W. Reid et al. · Nature Biotechnology
Open access |
Jul 2019 |
483 |
| 19 |
mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants
Kaichun Wu, Anne P. Werner, Juan I. Moliva et al. · bioRxiv (Cold Spring Harbor Laboratory)
PreprintOpen access |
25 Jan 2021 |
478 |
| 20 |
Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine
Kaichun Wu, Anne P. Werner, Matthew A. Koch et al. · New England Journal of Medicine
Open access |
17 Feb 2021 |
472 |
| 21 |
mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials
Robert Feldman, Rainard Fuhr, Igor V. Smolenov et al. · Vaccine
Open access |
May 2019 |
466 |
| 22 |
Applications of single-cell RNA sequencing in drug discovery and development
Bram Van de Sande, Joon Sang Lee, Euphemia Mutasa-Gottgens et al. · Nature Reviews Drug Discovery
ReviewOpen access |
28 Apr 2023 |
455 |
| 23 |
Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis
Angela Choi et al. · Nature Medicine
Open access |
15 Sep 2021 |
450 |
| 24 |
mRNA vaccine–induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer
Gal Cafri, Jared J. Gartner, Tal Z. Zaks et al. · Journal of Clinical Investigation
Open access |
4 Oct 2020 |
429 |
| 25 |
Emulation of Randomized Clinical Trials With Nonrandomized Database Analyses
Shirley V. Wang et al. · JAMA
Open access |
25 Apr 2023 |
414 |
| 26 |
Efficient Targeting and Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine Administration in Rhesus Macaques
Frank Liang, Gustaf Lindgren, Ang Lin et al. · Molecular Therapy
Open access |
14 Aug 2017 |
407 |
| 27 |
SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination
Rolando Pajon et al. · New England Journal of Medicine
Open access |
26 Jan 2022 |
395 |
| 28 |
SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines
Xiaoying Shen, Haili Tang, Charlene B. McDanal et al. · Cell Host & Microbe
Open access |
7 Mar 2021 |
394 |
| 29 |
A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial
Raffael Nachbagauer et al. · Nature Medicine
|
7 Dec 2020 |
367 |
| 30 |
Impact of lipid nanoparticle size on mRNA vaccine immunogenicity
Kimberly J. Hassett, Jaclyn S. Higgins, Angela L. Woods et al. · Journal of Controlled Release
Open access |
18 May 2021 |
365 |
| 31 |
Impact of mRNA chemistry and manufacturing process on innate immune activation
Jennifer A Nelson, Elizabeth W. Sorensen, Shrutika Mintri et al. · Science Advances
Open access |
24 Jun 2020 |
359 |
| 32 |
Novel approaches for vaccine development
Makda S. Gebre, Luis A. Brito, Lisa H. Tostanoski et al. · Cell
Open access |
Mar 2021 |
358 |
| 33 |
Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates
Kizzmekia S. Corbett et al. · Science
Open access |
29 Jul 2021 |
330 |
| 34 |
Durable anticancer immunity from intratumoral administration of IL-23, IL-36γ, and OX40L mRNAs
Susannah L. Hewitt, Ailin Bai, D. R. Shackleton Bailey et al. · Science Translational Medicine
|
30 Jan 2019 |
308 |
| 35 |
Hepatocyte-targeted RNAi Therapeutics for the Treatment of Chronic Hepatitis B Virus Infection
Christine I. Wooddell, David B. Rozema, Markus Hoßbach et al. · Molecular Therapy
Open access |
26 Feb 2013 |
294 |
| 36 |
Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer
Amir Massarweh, Noa Eliakim‐Raz, Amos Stemmer et al. · JAMA Oncology
Open access |
28 May 2021 |
290 |
| 37 |
N1-methyl-pseudouridine in mRNA enhances translation through eIF2α-dependent and independent mechanisms by increasing ribosome density
Yuri V. Svitkin, Yi Min Cheng, Tirtha Chakraborty et al. · Nucleic Acids Research
Open access |
21 Feb 2017 |
280 |
| 38 |
Prospects for a safe COVID-19 vaccine
Barton F. Haynes, Lawrence Corey, PRABHAVATHI B. FERNANDES et al. · Science Translational Medicine
|
19 Oct 2020 |
276 |
| 39 |
A novel mechanism for the loss of mRNA activity in lipid nanoparticle delivery systems
Meredith Packer, Dipendra Gyawali, Ravikiran Yerabolu et al. · Nature Communications
Open access |
22 Nov 2021 |
269 |
| 40 |
Systemic Messenger RNA Therapy as a Treatment for Methylmalonic Acidemia
An Ding et al. · Cell Reports
Open access |
Dec 2017 |
266 |
| 41 |
A systematic literature review of the global seroprevalence of cytomegalovirus: possible implications for treatment, screening, and vaccine development
Karen B. Fowler, Jacek Mucha, Monika Neumann et al. · BMC Public Health
ReviewOpen access |
Sep 2022 |
256 |
| 42 |
Boosting Intracellular Delivery of Lipid Nanoparticle-Encapsulated mRNA
Siddharth Patel, N. Ashwanikumar, Emily Robinson et al. · Nano Letters
Open access |
24 Aug 2017 |
252 |
| 43 |
An engineered T7 RNA polymerase that produces mRNA free of immunostimulatory byproducts
Athanasios D. Dousis, Kanchana R. Ravichandran, Elissa M. Hobert et al. · Nature Biotechnology
Open access |
10 Nov 2022 |
245 |
| 44 |
A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine
Laurence Chu, Roderick A. McPhee, Wenmei Huang et al. · Vaccine
Open access |
9 Feb 2021 |
240 |
| 45 |
Encapsulation state of messenger RNA inside lipid nanoparticles
Mark L. Brader, Sean J. Williams, Jessica M. Banks et al. · Biophysical Journal
Open access |
25 Mar 2021 |
237 |
| 46 |
Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity
Shinu A. John, Olga Yuzhakov, Angela L. Woods et al. · Vaccine
Open access |
15 Feb 2018 |
237 |
| 47 |
An RNA toolbox for cancer immunotherapy
Fernando Pastor, Pedro Berraondo, Iñaki Etxeberría et al. · Nature Reviews Drug Discovery
Review |
7 Sep 2018 |
230 |
| 48 |
mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron
Matthew Gagné et al. · Cell
Open access |
25 Mar 2022 |
229 |
| 49 |
Strategies to reduce the risks of mRNA drug and vaccine toxicity
Dimitrios Bitounis, Eric Jacquinet, Maximillian A. Rogers et al. · Nature Reviews Drug Discovery
Review |
23 Jan 2024 |
228 |
| 50 |
Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351
Xiaoying Shen, Haili Tang, Rolando Pajón et al. · New England Journal of Medicine
Open access |
7 Apr 2021 |
226 |